Abernethy AP, Postow MA, Chesney JA, Grossmann KF, Taylor F, Coon C, Gilloteau I, Dastani H, Gagnier P, Robert C (2015) Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069). J Clin Oncol 33:9029–9029

Article  Google Scholar 

Antoni MH, Dhabhar FS (2019) Impact of Psychosocial Stress and Stress Management on Immune Responses in Cancer Patients. Cancer 125:1417–1431

Article  PubMed  Google Scholar 

Bolick NL, Geller AC (2021) Epidemiology of Melanoma. Hematol Oncol Clin North Am 35:57–72

Article  PubMed  Google Scholar 

Boutros A, Bruzzone M, Tanda ET, Croce E, Arecco L, Cecchi F, Pronzato P, Ceppi M, Lambertini M (1990) Spagnolo F (2021): Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. Eur J Cancer Oxf Engl 159:154–166

Article  Google Scholar 

Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet Lond Engl 398:1002–1014

Article  CAS  Google Scholar 

Chen C, Wang Z, Qin YR (2023) Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Med 12(3):2262–2280

Article  CAS  PubMed  Google Scholar 

Cotté F-E, Voillot P, Bennett B, Falissard B, Tzourio C, Foulquié P, Gaudin A-F, Lemasson H, Grumberg V, McDonald L et al (2020) Exploring the health-related quality of life of patients treated with immune checkpoint inhibitors: Social Media Study. J Med Internet Res 22:e19694

Article  PubMed  PubMed Central  Google Scholar 

Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B et al (1990) (2021): Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. Eur J Cancer Oxf Engl 157:225–237

Article  Google Scholar 

Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep 22:39

Article  PubMed  Google Scholar 

Daud A, Blank CU, Robert C, Puzanov I, Richtig E, Margolin KA, O’Day S, Nyakas M, Lutzky J, Tarhini AA et al (2016) KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. J Clin Oncol 34:9513–9513

Article  Google Scholar 

Donovan KA, Deshields TL, Corbett C, Riba MB (2019) Update on the implementation of NCCN guidelines for distress management by NCCN member institutions. J Natl Compr Cancer Netw JNCCN 17:1251–1256

Article  PubMed  Google Scholar 

Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E et al (2023) Health-state utilities in long-term advanced melanoma survivors comparable with the general population. Qual Life Res 32:2517–2525

Article  CAS  PubMed  Google Scholar 

Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L (2024a) Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy. Eur J Cancer 200:113601

Article  CAS  PubMed  Google Scholar 

Egeler MD, van Leeuwen M, Lai-Kwon J, Eriksson H, Bartula I, Elashwah S, Fox L, Van Hemelrijck M et al (2024b) EORTC Quality of Life Group. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module. Eur J Cancer Oxf Engl 207:114176

Article  CAS  Google Scholar 

Eigentler T, Hoge J, Garbe C, Schadendorf D (2020): Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, AWMF Registernummer: 032/024OL, http://www.leitlinienprogramm- onkologie.de/leitlinien/melanom/ (abgerufen am: 17.06.2024)

Ellert U, Kurth B-M (2004) Methodological views on the SF-36 summary scores based on the adult German population. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1027–1032

Article  CAS  PubMed  Google Scholar 

Faury S, Foucaud J (2020) Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. PLoS ONE 15:e0227344

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forschner A, Riedel P, Gassenmaier M, Scheu A, Kofler L, Garbe C, Schäffeler N, Mayer S, Eigentler TK (2017) The demand for psycho-oncological support in 820 melanoma patients: What are the determinants for the development of distress? J Clin Oncol 35:9514–9514

Article  Google Scholar 

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B et al (2022) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer Oxf Engl 170:236–255

Article  Google Scholar 

Guerrisi A, Falcone I, Valenti F, Rao M, Gallo E, Ungania S, Maccallini MT, Fanciulli M, Frascione P, Morrone A, Caterino M (2022) Artificial intelligence and advanced melanoma: treatment management implications. Cells 11(24):3965. https://doi.org/10.3390/cells11243965

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO et al (2020) Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer 126:1550–1558

Article  PubMed  Google Scholar 

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480–1492

Article  CAS  PubMed  Google Scholar 

Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, Coebergh JW, Nijsten T (2011) Impact of melanoma on patients’ lives among 562 survivors: a Dutch population-based study. Arch Dermatol 147:177–185

Article  PubMed  Google Scholar 

Jackson-Carroll N, Johnson C, Tawbi H, Wang XS, Whisenant M (2024) The symptom experience of patients with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy. Semin Oncol Nurs 40:151574

Article  PubMed  Google Scholar 

Janke K-H, Klump B, Steder-Neukamm U, Hoffmann J, Häuser W (2006) Validation of the German version of the Inflammatory Bowel Disease Questionnaire (Competence Network IBD, IBDQ-D). Psychother Psychosom Med Psychol 56:291–298

Article  PubMed  Google Scholar 

Kasparian NA, McLoone JK, Butow PN (2009) Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 145:1415–1427

Article  PubMed  Google Scholar 

Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ (2021) Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore) 100:e26290

Article  CAS  PubMed  Google Scholar 

Knapp A, Harst L, Hager S, Schmitt J, Scheibe M (2021) Use of patient-reported outcome measures and patient-reported experience measures within evaluation studies of telemedicine applications: systematic review. J Med Internet Res 23:e30042

Article  PubMed  PubMed Central  Google Scholar 

Kungwengwe G, Gowthorpe C, Ali SR, Warren H, Drury DJ, Ang KL, Gibson JAG, Dobbs TD, Whitaker IS (2024) Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression. Br J Dermatol 191(1):24–35

Article  PubMed  Google Scholar 

Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I et al (2016) Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol off J Eur Soc Med Oncol 27:1940–1946

Article  CAS  Google Scholar 

Loquai C, Scheurich V, Syring N, Schmidtmann I, Rietz S, Werner A, Grabbe S, Beutel ME (2013) Screening for distress in routine oncological care-a survey in 520 melanoma patients. PLoS ONE 8:e66800

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machingura A, Taye M, Musoro J, Ringash J, Pe M, Coens C, Martinelli F, Tu D, Basch E, Brandberg Y et al (1990) (2022): Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. Eur J Cancer Oxf Engl 170:1–9

Google Scholar 

Mehnert A, Lehmann C, Cao P, Koch U (2006) Assessment of psychosocial distress and resources in oncology–a literature review about screening measures and current developments. Psychother Psychosom Med Psychol 56:462–479

Article  PubMed